Related Experiment Video
Updated: Sep 18, 2025
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.2K
Patients' Concerns About Receiving Preemptive Pharmacogenomic Testing: Results from a Large, Longitudinal Survey of
Joel E Pacyna1, Suzette J Bielinski2, Janet E Olson2
1Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN 55905, USA.
Journal of Personalized Medicine
|June 25, 2025
Summary
Patients generally have low concerns about preemptive pharmacogenomic (PGx) testing, but cost and insurance implications are key worries. Educational support can improve patient understanding and address these concerns effectively.
Area of Science:
- Pharmacogenomics
- Clinical Genetics
- Patient-Centered Care
Background:
- Increasing adoption of preemptive pharmacogenomic (PGx) testing in healthcare.
- Limited research on patient concerns regarding preemptive PGx information.
- Need to understand patient perspectives for successful implementation.
Purpose of the Study:
- To assess patient concerns about preemptive PGx testing.
- To evaluate concerns regarding data confidentiality, cost, comprehension, and medication regimens.
- To examine changes in concerns after receiving PGx results.
Main Methods:
- Longitudinal survey study of 5000 patients undergoing preemptive PGx testing (Mayo Clinic RIGHT study).
- Surveys administered before and after patients received PGx results.
- Assessed concerns related to insurance, out-of-pocket costs, result comprehension, and data privacy.
Main Results:
- High response rates (92.8% pre-results, 74.4% post-results).
- Overall low patient concern, but significant worries about insurance (25.5%) and out-of-pocket costs (30.1%).
- Concerns about costs and insurance significantly reduced post-results; comprehension difficulties persisted for some.
Conclusions:
- Healthcare institutions should address patient concerns regarding preemptive PGx testing.
- Educational interventions are crucial for improving understanding of PGx results.
- Proactive management of patient concerns is vital for successful PGx programs.
More Related Videos
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
11.1K
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
02:20Longitudinal Research
12.5K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
12.5K
01:12Analysis of Population Pharmacokinetic Data
397
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
397
01:28Preclinical Development: Overview
4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
01:11Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K
01:19Pharmacovigilance
1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K